KI67在卵巢癌组织中的表达及其与患者临床病理特征及预后的关系

Expression and clinical significance of KI67 in epithelial ovarian cancer

目的:分析卵巢癌组织中KI67蛋白的表达及其与患者临床病理特征及预后的关系。方法:收集172例卵巢癌患者(卵巢浆液性癌153例、黏液性癌3例、透明细胞癌2例、子宫内膜样腺癌13例、鳞状细胞癌1例)的卵巢癌组织石蜡标本,另同期收集8例卵巢良性肿瘤患者的卵巢肿瘤组织标本及10份正常卵巢组织标本作为对照。采用免疫组化方法检测KI67的表达情况,并分析其与卵巢癌患者临床病理特征及预后的关系。结果:KI67蛋白在卵巢癌组织中的阳性表达率为97.09%(167/172),明显高于正常卵巢组织及良性卵巢肿瘤组织(P<0.05)。KI67的表达与卵巢癌患者的年龄、是否浆液性卵巢癌、细胞分化程度、病理分期、是否淋巴结转移、无进展生存时间(PFS)及总生存时间(OS)均无明显相关关系(均P>0.05)。结论:卵巢癌患者KI67蛋白表达明显上调,KI67表达水平与卵巢癌患者的生存预后并无明显相关关系。

Objective： To investigate the expression of KI67 protein in patients with epithelial ovarian cancer and its clinical significance. Methods： Ovarian specimens were obtained from surgeries performed between 2005 and 2013. The patients were divided into three groups： group A, epithelial ovarian cancer （n= 172） ; group B, benign epithelial neoplasia （n = 8） ; and group C, normal ovaries （n = 10）. The protein expression of KI67 was measured by immunohistochemistry methods. The correlation between the KI67 expression and clinical pathological characteristics was analyzed. Results： The positive expression rate of KI67 protein was significantly higher in group A （97.09%） compared to group B and C （P〈0. 05）. There was no correlation between the expression of KI67 and age, serous ovarian cancer, cell differentiation, pathological stage, lymph node metastasis, progression-free survival （PFS） time and overall survival （OS） time of ovarian cancer patients （P〉0. 05）. Conclusion： KI67 protein expression was up-regulated in ovarian cancer patients and was not associated with survival prognosis of patients.